Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda raised the price target on Cytokinetics (NASDAQ: CYTK) to $86.00 (from $60.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
